Nvidia-backed Iambic Targets $806M Valuation in IPO
Iambic Therapeutics is aiming to raise up to $159 million in its upcoming US initial public offering. The Nvidia-backed biotech firm plans to list its shares on the Nasdaq under the ticker symbol IAM.
Xurve View
Insights:
Xurve View
Iambic Therapeutics, backed by NVIDIA CORP, is aiming to raise $159.4M in a United States IPO. The offering targets a valuation of up to $805.8M. The drugmaker's listing highlights biotech as a resilient sector in a subdued equity market.
